Biomaterials:化妆品中纳米级氧化锌存在致癌风险

2011-12-12 MedSci原创 MedSci原创

 MedSci评论:      纳米是未来制药领域重要的载体之一,原因在于它很容易进入细胞内(主动进入或被动吞噬),这一优良的特性使这成为药物载体的可能,但是,同样也会带来“纳米污染”,即纳米级的药物或分子,很容易进入无关或非治疗的细胞中,引发不可预料性的后果,尤其是致癌。有些物质,在细胞外,可能并不会破坏或影响DNA的合成,但是一旦进入细胞

 MedSci评论:
     纳米是未来制药领域重要的载体之一,原因在于它很容易进入细胞内(主动进入或被动吞噬),这一优良的特性使这成为药物载体的可能,但是,同样也会带来“纳米污染”,即纳米级的药物或分子,很容易进入无关或非治疗的细胞中,引发不可预料性的后果,尤其是致癌。有些物质,在细胞外,可能并不会破坏或影响DNA的合成,但是一旦进入细胞内,可能对DNA突变,合成或修复产生影响,从而诱导癌变或细胞凋亡。有关纳米污染,也是国际研究的热点之一。

11月30日,据海外媒体报道,新加坡研究团队发现防晒霜等化妆品中常见的成分氧化锌以纳米微粒状态使用时,可能致癌。

氧化锌属于物理性防晒成分,可阻隔紫外线,常用于防晒霜等化妆品。化妆品厂商为改善氧化锌本身的白色粘厚质地,多在产品中添加微粒较小的氧化锌成分。

新加坡南洋理工大学和新加坡国立大学的研究人员研究化妆品中的纳米材料时发现,皮肤细胞吸收纳米级氧化锌微粒后,人体会产生蛋白质p53以防止损伤的细胞复制,从而避免致癌。但一些人体内无法产生这种蛋白质,或产生的量不足,就可能导致癌症发生。

这项研究成果发表在新一期学术期刊《生物材料》上。研究人员强调,该研究不一定表明氧化锌会致癌,人们没必要因此惊慌。不过,化妆品厂商在添加纳米级氧化锌时,需重新谨慎评估其后果。

doi:10.1016/j.biomaterials.2011.07.036
The role of the tumor suppressor p53 pathway in the cellular DNA damage response to zinc oxide nanoparticles

Kee Woei Nga, Stella P.K. Khoob, Boon Chin Henga, Magdiel I. Setyawatic, Eng Chok Tanb, Xinxin Zhaoa, Sijing Xionga, Wanru Fangd, David T. Leongc, d, Corresponding Author Contact Information, E-mail The Corresponding Author, E-mail The Corresponding Author, Joachim S.C. Looa

In this paper, we explored how ZnO nanoparticles cross-interact with a critical tumor suppressive pathway centered around p53, which is one of the most important known tumor suppressors that protects cells from developing cancer phenotypes through its control over major pathways like apoptosis, senescence and cell cycle progression. We showed that the p53 pathway was activated in BJ cells (skin fibroblasts) upon ZnO nanoparticles treatment with a concomitant decrease in cell numbers. This suggests that cellular responses like apoptosis in the presence of ZnO nanoparticles require p53 as the molecular master switch towards programmed cell death. This also suggests that in cells without robust p53, protective response can be tipped towards carcinogenesis when stimulated by DNA damage inducing agents like ZnO nanoparticles. We observed this precarious tendency in the same BJ cells with p53 knocked down using endogeneous expressing shRNA. These p53 knocked down BJ cells became more resistant to ZnO nanoparticles induced cell death and increased cell progression. Collectively, our results suggest that cellular response towards specific nanoparticle induced cell toxicity and carcinogenesis is not only dependent on specific nanoparticle properties but also (perhaps more importantly) the endogenous genetic, transcriptomic and proteomic landscape of the target cells.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061303, encodeId=f199206130351, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Oct 27 02:02:00 CST 2012, time=2012-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916855, encodeId=b77d1916855c1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 12 12:02:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049961, encodeId=97eb204996191, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Apr 16 12:02:00 CST 2012, time=2012-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023308, encodeId=e84220233084a, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jul 02 04:02:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346882, encodeId=77241346882e1, content=<a href='/topic/show?id=75e0334e76e' target=_blank style='color:#2F92EE;'>#化妆品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33477, encryptionId=75e0334e76e, topicName=化妆品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370751, encodeId=ad4413e07514a, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]
    2012-10-27 sjq027
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061303, encodeId=f199206130351, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Oct 27 02:02:00 CST 2012, time=2012-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916855, encodeId=b77d1916855c1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 12 12:02:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049961, encodeId=97eb204996191, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Apr 16 12:02:00 CST 2012, time=2012-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023308, encodeId=e84220233084a, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jul 02 04:02:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346882, encodeId=77241346882e1, content=<a href='/topic/show?id=75e0334e76e' target=_blank style='color:#2F92EE;'>#化妆品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33477, encryptionId=75e0334e76e, topicName=化妆品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370751, encodeId=ad4413e07514a, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]
    2012-06-12 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061303, encodeId=f199206130351, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Oct 27 02:02:00 CST 2012, time=2012-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916855, encodeId=b77d1916855c1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 12 12:02:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049961, encodeId=97eb204996191, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Apr 16 12:02:00 CST 2012, time=2012-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023308, encodeId=e84220233084a, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jul 02 04:02:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346882, encodeId=77241346882e1, content=<a href='/topic/show?id=75e0334e76e' target=_blank style='color:#2F92EE;'>#化妆品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33477, encryptionId=75e0334e76e, topicName=化妆品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370751, encodeId=ad4413e07514a, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061303, encodeId=f199206130351, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Oct 27 02:02:00 CST 2012, time=2012-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916855, encodeId=b77d1916855c1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 12 12:02:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049961, encodeId=97eb204996191, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Apr 16 12:02:00 CST 2012, time=2012-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023308, encodeId=e84220233084a, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jul 02 04:02:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346882, encodeId=77241346882e1, content=<a href='/topic/show?id=75e0334e76e' target=_blank style='color:#2F92EE;'>#化妆品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33477, encryptionId=75e0334e76e, topicName=化妆品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370751, encodeId=ad4413e07514a, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061303, encodeId=f199206130351, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Oct 27 02:02:00 CST 2012, time=2012-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916855, encodeId=b77d1916855c1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 12 12:02:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049961, encodeId=97eb204996191, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Apr 16 12:02:00 CST 2012, time=2012-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023308, encodeId=e84220233084a, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jul 02 04:02:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346882, encodeId=77241346882e1, content=<a href='/topic/show?id=75e0334e76e' target=_blank style='color:#2F92EE;'>#化妆品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33477, encryptionId=75e0334e76e, topicName=化妆品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370751, encodeId=ad4413e07514a, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2061303, encodeId=f199206130351, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Oct 27 02:02:00 CST 2012, time=2012-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916855, encodeId=b77d1916855c1, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 12 12:02:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049961, encodeId=97eb204996191, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Apr 16 12:02:00 CST 2012, time=2012-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023308, encodeId=e84220233084a, content=<a href='/topic/show?id=bb29865199d' target=_blank style='color:#2F92EE;'>#致癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86519, encryptionId=bb29865199d, topicName=致癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jul 02 04:02:00 CST 2012, time=2012-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346882, encodeId=77241346882e1, content=<a href='/topic/show?id=75e0334e76e' target=_blank style='color:#2F92EE;'>#化妆品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33477, encryptionId=75e0334e76e, topicName=化妆品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370751, encodeId=ad4413e07514a, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Wed Dec 14 05:02:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]
    2011-12-14 jambiya

相关威廉亚洲官网

新纳米载药系统成功用于恶性肿瘤治疗

近日,国际著名学术期刊ACS nano和Biomaterials相继报道了中科院理化技术研究所研制的新型纳米载药系统在恶性肿瘤治疗及其生物安全性评价方面取得的新突破。 化疗药物在杀伤肿瘤细胞的同时,也将正常细胞一同杀灭,是一种“玉石俱焚”的癌症治疗方法。纳米药物载体可以增强药物的抗肿瘤效果,并且降低药物引起的毒副作用,大大减轻病人痛苦,延长生存期,为肿瘤治疗带来新的机遇。无机纳米材料是生物医学领

Acs Nano:李亚平等纳米载体降低肿瘤耐药研究获进展

近日,中科院上海药物研究所李亚平课题组与上海硅酸盐研究所施建林研究员课题组合作,在通过纳米载体调控细胞内药物释放降低肿瘤耐药研究中取得重要进展。相关研究结果发表在纳米技术领域期刊Acs Nano。 多药耐药现象是癌症治疗的主要障碍之一,而化疗药物的纳米输送系统有望提高对耐药肿瘤的治疗效果。上海硅酸盐所施建林课题组长期致力于介孔二氧化硅纳米粒(MSNs)的制备和应用基础研究,而上海药物所李亚平研究